What is Black Diamond Therapeutics, Inc.'s earnings per share (EPS)?

Black Diamond Therapeutics, Inc. (BDTX) reported diluted earnings per share of $0.39 for fiscal year 2025. This represents a 130.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Black Diamond Therapeutics, Inc. Financials

BDTX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Black Diamond Therapeutics, Inc. (BDTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BDTX FY2025 2026-05-07

FY2025 marks a shift from an equity-funded R&D burn to a cash-generating operating model with modest liabilities.

FY2025 did more than introduce $70M of revenue: it flipped both operating income to $12.5M and operating cash flow to $29.6M after cash burn of -$66.7M in FY2023 and -$62.3M in FY2024. That shift also changed the financing posture, with financing cash flow moving from $71.9M and $25.5M of prior support to roughly flat in FY2025, so the core business was no longer being funded mainly by new capital.

Profitability improved through both scale and a smaller cost base, not from revenue alone: R&D expense fell to $33.6M from $51.3M in FY2024, while SG&A dropped to $16.6M from $27.5M. That means the FY2025 margin step-up reflects deliberate spending compression as well as new revenue.

Cash conversion was stronger than the income statement alone suggests, because operating cash flow of $29.6M exceeded net income of $22.4M. Cash still fell to $21.0M from $36.4M because investing uses consumed $44.9M, but a current ratio of 8.4x and total liabilities of only $30.8M left near-term obligations light.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Black Diamond Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Black Diamond Therapeutics, Inc. has an operating margin of 17.9%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 85/100, reflecting efficient cost management and pricing power.

Leverage

Black Diamond Therapeutics, Inc. carries a low D/E ratio of 0.27, meaning only $0.27 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 70/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 8.42, Black Diamond Therapeutics, Inc. holds $8.42 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 96/100.

Altman Z-Score Distress

-0.67

Black Diamond Therapeutics, Inc. scores -0.67, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($108.9M) relative to total liabilities ($30.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$70.0M

Black Diamond Therapeutics, Inc. generated $70.0M in revenue in fiscal year 2025.

EBITDA

$12.8M

YoY+116.4%

Black Diamond Therapeutics, Inc.'s EBITDA was $12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 116.4% from the prior year.

Net Income

N/A

EPS (Diluted)

$0.39

YoY+130.7%

Black Diamond Therapeutics, Inc. earned $0.39 per diluted share (EPS) in fiscal year 2025. This represents an increase of 130.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$21.0M

YoY-42.4%

5Y CAGR-9.5%

Black Diamond Therapeutics, Inc. held $21.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

57M

YoY+0.9%

5Y CAGR+9.6%

Black Diamond Therapeutics, Inc. had 57M shares outstanding in fiscal year 2025. This represents an increase of 0.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

17.9%

Black Diamond Therapeutics, Inc.'s operating margin was 17.9% in fiscal year 2025, reflecting core business profitability.

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$33.6M

YoY-34.6%

5Y CAGR-7.0%

Black Diamond Therapeutics, Inc. invested $33.6M in research and development in fiscal year 2025. This represents a decrease of 34.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BDTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$70.0M	$0	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.6M-34.6%	$51.3M-13.5%	$59.4M-7.9%	$64.4M-33.5%	$96.8M+100.9%	$48.2M
SG&A Expenses	$16.6M-39.7%	$27.5M+1.3%	$27.1M-4.5%	$28.4M-5.5%	$30.0M+40.6%	$21.4M
Operating Income	$12.5M+115.9%	-$78.8M+8.9%	-$86.5M+6.9%	-$92.8M+26.8%	-$126.9M-82.4%	-$69.6M
Interest Expense	N/A	N/A	N/A	N/A	$0-100.0%	$1K
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	N/A	N/A	-$82.4M+9.6%	-$91.2M+27.4%	-$125.6M-86.7%	-$67.3M
EPS (Diluted)	$0.39+130.7%	$-1.27+32.4%	$-1.88+25.4%	$-2.52+27.4%	$-3.47-69.3%	$-2.05

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$0	N/A	$0	$0-100.0%	$70.0M	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7.0M	N/A	$7.4M-20.2%	$9.3M-11.3%	$10.5M	N/A	$12.9M+2.9%	$12.6M
SG&A Expenses	$4.3M	N/A	$3.5M-13.7%	$4.1M-17.4%	$5.0M	N/A	$5.2M-45.5%	$9.6M
Operating Income	-$11.3M	N/A	-$11.0M+18.2%	-$13.4M-124.6%	$54.5M	N/A	-$18.1M+18.1%	-$22.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	$226K	N/A	N/A	N/A
Net Income	-$9.0M	N/A	-$8.5M+19.5%	-$10.6M-118.7%	$56.5M	N/A	-$15.6M+21.9%	-$19.9M
EPS (Diluted)	$-0.16	N/A	$-0.15+21.1%	$-0.19-119.4%	$0.98	N/A	$-0.28+22.2%	$-0.36

BDTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$143.0M+16.6%	$122.6M-22.7%	$158.6M+1.5%	$156.3M-36.9%	$247.7M-24.9%	$329.7M
Current Assets	$132.4M+30.9%	$101.2M-24.5%	$134.0M+5.0%	$127.7M-40.8%	$215.7M-32.5%	$319.6M
Cash & Equivalents	$21.0M-42.4%	$36.4M-35.2%	$56.2M+63.8%	$34.3M-47.8%	$65.8M+90.1%	$34.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$30.8M-21.7%	$39.4M-5.9%	$41.8M+3.1%	$40.6M-21.7%	$51.8M+136.3%	$21.9M
Current Liabilities	$15.7M-23.5%	$20.6M+4.7%	$19.6M+28.7%	$15.3M-35.4%	$23.6M+66.3%	$14.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$112.2M+34.7%	$83.3M-28.7%	$116.7M+0.9%	$115.7M-40.9%	$195.9M-36.3%	$307.8M
Retained Earnings	-$464.7M+4.6%	-$487.1M-16.7%	-$417.4M-24.6%	-$335.0M-37.4%	-$243.8M-106.2%	-$118.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$132.9M-7.1%	$143.0M-9.3%	$157.7M-5.2%	$166.4M-5.6%	$176.2M+43.7%	$122.6M-11.1%	$137.9M-8.1%	$150.0M
Current Assets	$123.0M-7.2%	$132.4M-4.7%	$139.0M-5.3%	$146.7M-5.8%	$155.7M+53.9%	$101.2M-12.4%	$115.5M-8.8%	$126.8M
Cash & Equivalents	$30.1M+43.3%	$21.0M-32.0%	$30.9M+2.9%	$30.0M-69.5%	$98.4M+170.1%	$36.4M+55.5%	$23.4M-28.6%	$32.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$28.6M-7.1%	$30.8M-2.5%	$31.6M-6.5%	$33.8M-2.7%	$34.7M-11.8%	$39.4M-2.8%	$40.5M+3.9%	$39.0M
Current Liabilities	$14.5M-7.6%	$15.7M+1.2%	$15.5M-7.5%	$16.8M-0.2%	$16.8M-18.1%	$20.6M-1.1%	$20.8M+12.8%	$18.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$104.3M-7.1%	$112.2M-11.1%	$126.2M-4.9%	$132.6M-6.3%	$141.5M+69.9%	$83.3M-14.5%	$97.4M-11.8%	$110.5M
Retained Earnings	-$473.8M-1.9%	-$464.7M-3.4%	-$449.6M-1.9%	-$441.1M-2.5%	-$430.6M+11.6%	-$487.1M-3.4%	-$471.1M-3.4%	-$455.6M

BDTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$29.6M+147.5%	-$62.3M+6.6%	-$66.7M+21.6%	-$85.1M+15.0%	-$100.1M-92.1%	-$52.1M
Capital Expenditures	N/A	$0-100.0%	$33K-82.8%	$192K-92.9%	$2.7M+1808.5%	$142K
Free Cash Flow	N/A	-$62.3M+6.7%	-$66.8M+21.7%	-$85.3M+17.1%	-$102.9M-96.7%	-$52.3M
Investing Cash Flow	-$44.9M-364.6%	$17.0M+3.8%	$16.3M-69.4%	$53.4M-59.1%	$130.6M+146.4%	-$281.7M
Financing Cash Flow	-$146K-100.6%	$25.5M-64.5%	$71.9M+40539.5%	$177K-75.7%	$729K-99.7%	$214.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$10.2M-50.8%	-$6.8M+13.5%	-$7.8M+14.3%	-$9.2M-117.1%	$53.4M+454.8%	-$15.1M-33.0%	-$11.3M+23.1%	-$14.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$15.1M	N/A	N/A
Investing Cash Flow	$19.5M+775.0%	-$2.9M-133.6%	$8.6M+114.5%	-$59.2M-792.1%	$8.5M-69.2%	$27.8M+1166.3%	$2.2M+196.4%	$740K
Financing Cash Flow	-$185K+5.6%	-$196K-246.3%	$134K+215.5%	-$116K-462.5%	$32K-89.0%	$291K+215.5%	-$252K-101.2%	$21.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BDTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	17.9%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-70.6%+8.2pp	-78.8%-14.7pp	-64.1%-42.3pp	-21.9%
Return on Assets	N/A	N/A	-52.0%+6.4pp	-58.4%-7.6pp	-50.7%-30.3pp	-20.4%
Current Ratio	8.42+3.5	4.92-1.9	6.82-1.5	8.37-0.8	9.12-13.4	22.48
Debt-to-Equity	0.27-0.2	0.47+0.1	0.360.0	0.35+0.1	0.26+0.2	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-16.1%	N/A	N/A	N/A	77.9%	N/A	N/A	N/A
Net Margin	-12.9%	N/A	N/A	N/A	80.8%	N/A	N/A	N/A
Return on Equity	-8.7%	N/A	-6.7%+1.2pp	-8.0%-47.9pp	40.0%	N/A	-16.0%+2.0pp	-18.0%
Return on Assets	-6.8%	N/A	-5.4%+1.0pp	-6.3%-38.4pp	32.1%	N/A	-11.3%+2.0pp	-13.3%
Current Ratio	8.46+0.0	8.42-0.5	8.94+0.2	8.73-0.5	9.24+4.3	4.92-0.6	5.55-1.3	6.87
Debt-to-Equity	0.270.0	0.27+0.0	0.250.0	0.250.0	0.25-0.2	0.47+0.1	0.42+0.1	0.35
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

C4 Therapeutics, Inc. CCCC

$433.4M

Elicio Therapeutics, Inc. ELTX

$86.4M

NeOnc Technologies Holdings Inc NTHI

$112.0M

Kyverna Therapeutics KYTX

$472.4M

Nuvectis Pharma, Inc. NVCT

$581.3M

Frequently Asked Questions

What is Black Diamond Therapeutics, Inc.'s annual revenue?

Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

What is Black Diamond Therapeutics, Inc.'s EBITDA?

Black Diamond Therapeutics, Inc. (BDTX) had EBITDA of $12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Black Diamond Therapeutics, Inc.'s operating margin?

Black Diamond Therapeutics, Inc. (BDTX) had an operating margin of 17.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Black Diamond Therapeutics, Inc.'s operating cash flow?

Black Diamond Therapeutics, Inc. (BDTX) generated $29.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Black Diamond Therapeutics, Inc.'s total assets?

Black Diamond Therapeutics, Inc. (BDTX) had $143.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Black Diamond Therapeutics, Inc. spend on research and development?

Black Diamond Therapeutics, Inc. (BDTX) invested $33.6M in research and development during fiscal year 2025.

How many shares does Black Diamond Therapeutics, Inc. have outstanding?

Black Diamond Therapeutics, Inc. (BDTX) had 57M shares outstanding as of fiscal year 2025.

What is Black Diamond Therapeutics, Inc.'s current ratio?

Black Diamond Therapeutics, Inc. (BDTX) had a current ratio of 8.42 as of fiscal year 2025, which is generally considered healthy.

What is Black Diamond Therapeutics, Inc.'s debt-to-equity ratio?

Black Diamond Therapeutics, Inc. (BDTX) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Black Diamond Therapeutics, Inc.'s Altman Z-Score?

Black Diamond Therapeutics, Inc. (BDTX) has an Altman Z-Score of -0.67, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

How financially healthy is Black Diamond Therapeutics, Inc.?

Black Diamond Therapeutics, Inc. (BDTX) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.